Biotechnology company Genentech was granted the approval for Polivy, to be used in combination with the chemotherapy bendamustine and a rituximab product (a combination known as BR) to treat adult patients with diffuse large B-cell
lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
Nordic Nanovector ASA (OSE: NANO), a developer of targeted therapies for haematological cancers, reported on Tuesday that the results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell
tumours are promising.
According to some recent studies, the GZLs have poorer outcome as compared to other aggressive B-cell
lymphomas.22 However, all our patients are doing well after end of treatment until their last follow ups as mentioned above.
The data were obtained from the medical histories of patients and the following characteristics were analyzed: sex, age at the time of diagnosis, germinal center B-cell
(GCB)/non-GCB subtype , initial treatment, time of disease relapse (early relapse [less than or equal to] 12 months from the end of the first-line treatment, late relapse > 12 months from the end of the first line of treatment).
Primary cutaneous follicle center lymphoma is the most-common primary cutaneous B-cell
Rituximab along with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is a proven standard chemotherapy treatment, which regulates the clinical course and reduces the relapse rate in patients with CD20-positive B-cell
epitope is the antigen portion binding to the immunoglobulin or antibody.
In addition, the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for Kymriah for the treatment of children and young adults with r/r B-cell
acute lymphoblastic leukemia (ALL) and for adult patients with r/r DLBCL who are ineligible for ASCT.
Immunohistochemical staining performed on thyroid gland revealed a B-cell
phenotype (positive for CD20 (Figure 2(a)), dim CD79a (Figure 2(b)), and dim PAX-5 and also positive for MUM-1 (Figure 2(c)), CD5 (Figure 2(d)), and dim CD30.
Diffuse large B-cell
lymphoma (DLBCL) is the most common lymphoid neoplasms in adults; accounting for approximately 32.5% of NHLs diagnosed annually.1 Secondary central nervous system (CNS) involvement in DLBCL includes an isolated CNS relapse or CNS involvement with systemic disease.
Typically, T-cell populations promote B-cell
response in the synovium but the mechanism for the overall cellular response is unclear.
Our study was designed to explore the microRNA-155 (miR-155) expression levels in peripheral blood mononuclear cells (PBMCs) in patients with various subtypes of B-cell
lymphocytosis is accepted as an important risk factor for developing lymphocytosis familial chronic lymphocytic leukemia (CLL) but does not meet the criteria for B-cell
lymphoproliferative disease, and patients with <5,000 (but not 0) CLL-phenotype B-cell
lymphocytes per [mm.sup.3].